Project Grant R01AI200742
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $937K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $1.097 million on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop germline-targeted HIV vaccines using membrane ENV liposomes designed to elicit broadly neutralizing antibodies against the membrane-proximal external region (MPER) of the HIV envelope glycoprotein. The research program uses a vaccine platform (membrane ENV liposomes) that displays...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $511,531 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance HIV vaccine development using a lipid nanodisc platform. The project, designated R01AI192143, addresses challenges in engineering transmembrane HIV envelope glycoprotein (ENV) vaccine candidates by incorporating them into stable lipid nanodiscs using membrane scaffold proteins and...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $931,385 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to glycoengineer core alpha(1,3)-fucose motifs into HIV-1 envelope vaccine immunogens to enhance neutralizing antibody responses. The recipient is developing glycoengineered cell lines expressing alpha(1,3)-fucose that enable production of highly immunogenic HIV-1 envelope trimers suitable for...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scripps Research Institute a $3.02 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning August 8, 2025, with a completion date of July 31, 2029. This award supports the design and development of single-shot sequential immunization regimens for HIV using atomic layer deposition (ALD) technology. The research builds upon preclinical successes...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $552,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct functional characterization of dendritic cell heterogeneity for T cell-inducing immunotherapies. The research addresses vaccine development for intracellular pathogens including HIV/AIDS and malaria by investigating the distinct roles of type 1 and type 2 conventional dendritic cells in...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $865,432 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the mechanisms of action of saponin combination adjuvants for vaccine development. The award funds research into saponin/monophosphoryl lipid A nanoparticles (SMNP), cage-like nanostructures that combine saponins derived from the Chilean soapbark tree with a Toll-like receptor-4 agonist. The...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $253,256 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model through May 31, 2028. The project develops a preclinical platform for engineered B cell therapies aimed at creating a functional HIV cure. Scripps will determine whether immunoglobulin heavy chain...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...